上海交通大学学报（医学版）
上海交通大學學報（醫學版）
상해교통대학학보（의학판）
JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY(MEDICAL SCIENCE)
2010年
4期
448-451
,共4页
杜光烨%李小强%刘立伟%陆玲娟%董君波
杜光燁%李小彊%劉立偉%陸玲娟%董君波
두광엽%리소강%류립위%륙령연%동군파
甲状腺乳头状癌%甲状腺乳头状增生%Cytokeratin%19%HBME-1%Galeetin-3%鉴别诊断
甲狀腺乳頭狀癌%甲狀腺乳頭狀增生%Cytokeratin%19%HBME-1%Galeetin-3%鑒彆診斷
갑상선유두상암%갑상선유두상증생%Cytokeratin%19%HBME-1%Galeetin-3%감별진단
thyroid papillary carcinoma%thyroid papillary hyperplasia%Cytokeratin 19%HBME-1%Galectin-3%differential diagnosis
目的 探讨Cytokeratin 19(CKl9)、HBME-1和Galectin-3在甲状腺乳头状癌和乳头状增生性甲状腺疾病鉴别诊断中的作用.方法 收集289例甲状腺切除标本,包括144例经典型乳头状癌(CPC)、21例滤泡型乳头状癌(FVPC)、19例乳头状微小癌(PM)、46例结节性甲状腺肿伴乳头状增生(NGWPH)和59例甲状腺腺瘤伴乳头状增生(FAWPH),采用EnVision二步法检测CKl9、HBME-1和Galectin-3的表达.结果 CK19、HBME-1和Galectin-3在CPC中的阳性表达率分别为100%、93.1%和89.6%,在FVPC中为100%、76.2%和76.2%,在PM中为100%、73.7%和78.9%,在NGWPH中为5.1%、2.2%和4.3%,在FAWPH中为4.3%、1.7%和5.1%.CKl9、HBME-1和Galectin-3的阳性表达率在乳头状癌与乳头状增生性甲状腺疾病之间比较,差异均有统计学意义(P<0.01).结论 在甲状腺乳头状癌鉴别诊断中,CK19的敏感性较高,HBME-1和Galectin-3特异性较强;三种抗体联合应用,有助于鉴别甲状腺乳头状癌与乳头状增生.
目的 探討Cytokeratin 19(CKl9)、HBME-1和Galectin-3在甲狀腺乳頭狀癌和乳頭狀增生性甲狀腺疾病鑒彆診斷中的作用.方法 收集289例甲狀腺切除標本,包括144例經典型乳頭狀癌(CPC)、21例濾泡型乳頭狀癌(FVPC)、19例乳頭狀微小癌(PM)、46例結節性甲狀腺腫伴乳頭狀增生(NGWPH)和59例甲狀腺腺瘤伴乳頭狀增生(FAWPH),採用EnVision二步法檢測CKl9、HBME-1和Galectin-3的錶達.結果 CK19、HBME-1和Galectin-3在CPC中的暘性錶達率分彆為100%、93.1%和89.6%,在FVPC中為100%、76.2%和76.2%,在PM中為100%、73.7%和78.9%,在NGWPH中為5.1%、2.2%和4.3%,在FAWPH中為4.3%、1.7%和5.1%.CKl9、HBME-1和Galectin-3的暘性錶達率在乳頭狀癌與乳頭狀增生性甲狀腺疾病之間比較,差異均有統計學意義(P<0.01).結論 在甲狀腺乳頭狀癌鑒彆診斷中,CK19的敏感性較高,HBME-1和Galectin-3特異性較彊;三種抗體聯閤應用,有助于鑒彆甲狀腺乳頭狀癌與乳頭狀增生.
목적 탐토Cytokeratin 19(CKl9)、HBME-1화Galectin-3재갑상선유두상암화유두상증생성갑상선질병감별진단중적작용.방법 수집289례갑상선절제표본,포괄144례경전형유두상암(CPC)、21례려포형유두상암(FVPC)、19례유두상미소암(PM)、46례결절성갑상선종반유두상증생(NGWPH)화59례갑상선선류반유두상증생(FAWPH),채용EnVision이보법검측CKl9、HBME-1화Galectin-3적표체.결과 CK19、HBME-1화Galectin-3재CPC중적양성표체솔분별위100%、93.1%화89.6%,재FVPC중위100%、76.2%화76.2%,재PM중위100%、73.7%화78.9%,재NGWPH중위5.1%、2.2%화4.3%,재FAWPH중위4.3%、1.7%화5.1%.CKl9、HBME-1화Galectin-3적양성표체솔재유두상암여유두상증생성갑상선질병지간비교,차이균유통계학의의(P<0.01).결론 재갑상선유두상암감별진단중,CK19적민감성교고,HBME-1화Galectin-3특이성교강;삼충항체연합응용,유조우감별갑상선유두상암여유두상증생.
Objective To investigate the value of Cytokeratin 19 ( CK19), HBME-1 and Galectin-3 in differential diagnosis of papillary carcinoma of thyroid and thyroid disease with papillary hyperplasia. Methods The specimens of 289 cases of thyroid lesions, including 144 cases of classic papillary carcinoma (CPC), 21 cases of follicular variant papillary carcinoma ( FVPC), 19 cases of papillary microcarcinoma (PM), 46 cases of nodular goiter with papillary hyperplasia ( NGWPH) and 59 cases of follicular adenoma with papillary hyperplasia (FAWPH) were collected. The expression of CK19, HBME-1 and Galectin-3 was detected by EnVision system. Results CK19, HBME-1 and Galectin-3 expressed in 100%, 93.1% and 89.6% of CPC, in 100%, 76.2% and 76. 2% of FVPC, in 100%, 73.7% and 78. 9% of PM, in 5.1%, 2.2% and 4.3% of NGWPH, and in 4. 3%, 1.7% and 5.1% of FAWPH, respectively. There were significant differences between thyroid papillary carcinoma and thyroid diseases with papillary hyperplasia in expression of CK19, HBME-1 and Galectin-3 (P<0.01). Conclusion CK19 is a sensitive marker for thyroid papillary carcinoma, and HBME-1 and Galectin-3 are better in specificity. This panel of markers is useful to differentiate papillary carcinoma of thyroid from thyroid papillary hyperplasia.
